ArticleMolecular cancer2023

Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.

Yunlin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.